BioVie to present new biomarker data from Phase 2 bezisterim Long COVID trial
BIVI•BioVie will present Phase 2 bezisterim Long COVID findings, including previously undisclosed biomarker data, on November 13, 2026, in Nice, France. The ADDRESS-LC trial showed consistent improvement trends, with prespecified analyses finding statistically significant improvements among patients with more severe symptoms.
1. Trial findings
BioVie said it will present findings from its randomized, placebo-controlled ADDRESS-LC trial on November 13, 2026, in Nice, France, including previously undisclosed biomarker data. The trial showed a consistent trend toward improvement across most patient-reported and objective efficacy measures; prespecified exploratory analyses found the greatest benefits, including statistically significant improvements, among patients with more severe fatigue, post-exertional malaise or cognitive impairment.
